Details of the Drug

General Information of Drug (ID: DM0GUSX)

Drug Name
Ranitidine
Synonyms
Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Indication
Disease Entry ICD 11 Status REF
Gastric ulcer DA60 Approved [1]
Gastrinoma 2C10.1 Approved [1]
Peptic ulcer DA61 Approved [2]
Therapeutic Class
Antiulcer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 314.41
Logarithm of the Partition Coefficient (xlogp) 0.3
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 12-16 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
The bioavailability of drug is 90-93% [3]
Clearance
The renal clearance of drug is 410 mL/min [5]
Elimination
About 30% of a single oral dose has been measured in the urine as unchanged drug within 24 hours of ingestion [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 - 3 hours [6]
Metabolism
The drug is metabolized via the liver [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 28.5 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.95% [8]
Vd
The volume of distribution (Vd) of drug is 1.4 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 555 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Vitamin B12 deficiency Not Available GIF OTNE20WU [9]
Chemical Identifiers
Formula
C13H22N4O3S
IUPAC Name
(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
Canonical SMILES
CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C
InChI
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
InChIKey
VMXUWOKSQNHOCA-UKTHLTGXSA-N
Cross-matching ID
PubChem CID
3001055
ChEBI ID
CHEBI:8776
CAS Number
82530-72-1
DrugBank ID
DB00863
TTD ID
D0B8WN
VARIDT ID
DR00163
INTEDE ID
DR1393
ACDINA ID
D00583
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [11]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [12]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [11]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [14]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [15]
Dimethylaniline oxidase 5 (FMO5) DEBMX7C FMO5_HUMAN Substrate [16]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Gene/Protein Processing [17]
Cobalamin binding intrinsic factor (CBLIF) OTNE20WU IF_HUMAN Drug Response [9]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Regulation of Drug Effects [18]
Gastrin (GAST) OTD0IP9N GAST_HUMAN Gene/Protein Processing [19]
Organic anion transporter 3 (SLC22A8) OT8BY933 S22A8_HUMAN Regulation of Drug Effects [11]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Protein Interaction/Cellular Processes [20]
Protachykinin-1 (TAC1) OTM842YW TKN1_HUMAN Gene/Protein Processing [17]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [21]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Regulation of Drug Effects [12]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Regulation of Drug Effects [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ranitidine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased absorption of Ranitidine due to formation of complexes caused by Sarecycline . Acne vulgaris [ED80] [22]
Cefuroxime DMSIMD8 Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Cefuroxime. Acute bronchitis [CA42] [23]
Glibenclamide DM8JXPZ Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Glibenclamide. Acute diabete complication [5A2Y] [24]
Glipizide DMZA5PQ Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Glipizide. Acute diabete complication [5A2Y] [24]
Rivastigmine DMG629M Moderate Antagonize the effect of Ranitidine when combined with Rivastigmine. Alzheimer disease [8A20] [25]
Nifedipine DMSVOZT Minor Decreased metabolism of Ranitidine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [26]
Posaconazole DMUL5EW Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Posaconazole. Aspergillosis [1F20] [27]
Aminophylline DML2NIB Moderate Decreased metabolism of Ranitidine caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [28]
Cefpodoxime DMJUNY5 Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [23]
Bacampicillin DMP54C7 Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [23]
Omadacycline DMR2J95 Moderate Decreased absorption of Ranitidine due to formation of complexes caused by Omadacycline. Bacterial infection [1A00-1C4Z] [22]
Cefditoren DMSUVM1 Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Cefditoren. Bacterial infection [1A00-1C4Z] [29]
Minocycline DMVN5OH Moderate Decreased absorption of Ranitidine due to formation of complexes caused by Minocycline. Bacterial infection [1A00-1C4Z] [22]
Vismodegib DM5IXKQ Minor Decreased absorption of Ranitidine due to altered gastric pH caused by Vismodegib. Basal cell carcinoma [2C32] [30]
Pexidartinib DMS2J0Z Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [31]
Lapatinib DM3BH1Y Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Lapatinib. Breast cancer [2C60-2C6Y] [32]
HKI-272 DM6QOVN Major Decreased absorption of Ranitidine due to altered gastric pH caused by HKI-272. Breast cancer [2C60-2C6Y] [30]
Bosutinib DMTI8YE Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Bosutinib. Breast cancer [2C60-2C6Y] [32]
Atracurium DM42HXN Minor Antagonize the effect of Ranitidine when combined with Atracurium. Corneal disease [9A76-9A78] [33]
Mivacurium DM473VD Minor Antagonize the effect of Ranitidine when combined with Mivacurium. Corneal disease [9A76-9A78] [33]
Pancuronium DMB0VY8 Minor Antagonize the effect of Ranitidine when combined with Pancuronium. Corneal disease [9A76-9A78] [33]
Tubocurarine DMBZIVP Minor Antagonize the effect of Ranitidine when combined with Tubocurarine. Corneal disease [9A76-9A78] [33]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Ranitidine caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [28]
Lumacaftor DMCLWDJ Moderate Accelerated clearance of Ranitidine due to the transporter induction by Lumacaftor. Cystic fibrosis [CA25] [32]
Itraconazole DMCR1MV Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Itraconazole. Fungal infection [1F29-1F2F] [34]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [35]
GS-5885 DMSL3DX Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by GS-5885. Hepatitis virus infection [1E50-1E51] [36]
Fosamprenavir DM4W9B3 Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Fosamprenavir. Human immunodeficiency virus disease [1C60-1C62] [37]
Didanosine DMI2QPE Minor Decreased absorption of Ranitidine due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [38]
Rilpivirine DMJ0QOW Major Decreased absorption of Ranitidine due to altered gastric pH caused by Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [39]
Atazanavir DMSYRBX Major Decreased absorption of Ranitidine due to altered gastric pH caused by Atazanavir. Human immunodeficiency virus disease [1C60-1C62] [32]
Raltegravir DMYURI6 Minor Decreased absorption of Ranitidine due to altered gastric pH caused by Raltegravir. Human immunodeficiency virus disease [1C60-1C62] [40]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Ranitidine caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [41]
Triazolam DMETYK5 Moderate Increased metabolism of Ranitidine caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [42]
Physostigmine DM2N0TO Moderate Antagonize the effect of Ranitidine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [25]
Ceritinib DMB920Z Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Ceritinib. Lung cancer [2C25] [43]
Dacomitinib DMOH8VY Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Dacomitinib. Lung cancer [2C25] [32]
Selpercatinib DMZR15V Major Decreased absorption of Ranitidine due to altered gastric pH caused by Selpercatinib. Lung cancer [2C25] [32]
Acalabrutinib DM7GCVW Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Acalabrutinib. Mature B-cell lymphoma [2A85] [44]
Ponatinib DMYGJQO Minor Decreased absorption of Ranitidine due to altered gastric pH caused by Ponatinib. Mature B-cell lymphoma [2A85] [30]
Dabrafenib DMX6OE3 Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Dabrafenib. Melanoma [2C30] [30]
Flibanserin DM70DTN Moderate Decreased metabolism of Ranitidine caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [45]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Ranitidine and Thalidomide. Multiple myeloma [2A83] [30]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Ranitidine and Siponimod. Multiple sclerosis [8A40] [30]
Fingolimod DM5JVAN Moderate Increased risk of atrioventricular block by the combination of Ranitidine and Fingolimod. Multiple sclerosis [8A40] [46]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Ranitidine and Ozanimod. Multiple sclerosis [8A40] [47]
Nilotinib DM7HXWT Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Nilotinib. Myeloproliferative neoplasm [2A20] [30]
Dasatinib DMJV2EK Major Decreased absorption of Ranitidine due to altered gastric pH caused by Dasatinib. Myeloproliferative neoplasm [2A20] [48]
Prasugrel DM7MT6E Minor Decreased absorption of Ranitidine due to altered gastric pH caused by Prasugrel. Myocardial infarction [BA41-BA43] [49]
Axitinib DMGVH6N Minor Decreased absorption of Ranitidine due to altered gastric pH caused by Axitinib. Renal cell carcinoma [2C90] [50]
Vandetanib DMRICNP Minor Decreased absorption of Ranitidine due to altered gastric pH caused by Vandetanib. Solid tumour/cancer [2A00-2F9Z] [30]
Pipecuronium DM5F84A Minor Antagonize the effect of Ranitidine when combined with Pipecuronium. Tonus and reflex abnormality [MB47] [33]
Doxacurium DMKE7L9 Minor Antagonize the effect of Ranitidine when combined with Doxacurium. Tonus and reflex abnormality [MB47] [33]
Vecuronium DMP0UK2 Minor Antagonize the effect of Ranitidine when combined with Vecuronium. Tonus and reflex abnormality [MB47] [33]
Tolbutamide DM02AWV Moderate Decreased absorption of Ranitidine due to altered gastric pH caused by Tolbutamide. Type 2 diabetes mellitus [5A11] [24]
Procainamide DMNMXR8 Moderate Decreased elimination of Ranitidine caused by Procainamide mediated competitive inhibition of renal tubular secretion. Ventricular tachyarrhythmia [BC71] [51]
⏷ Show the Full List of 56 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylparaben E00142 7184 Antimicrobial preservative
D&C red no. 30 E00456 3000709 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Potassium phosphate monobasic E00429 516951 Buffering agent
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Saccharin sodium anhydrous E00443 656582 Flavoring agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Vanillin E00049 1183 Flavoring agent
Phenol E00038 996 Antimicrobial preservative
Acetyltriethyl citrate E00126 6504 Plasticizing agent
Ammonia E00007 222 Alkalizing agent
Carmellose sodium E00625 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Disodium hydrogenorthophosphate E00283 24203 Buffering agent; Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium phosphate dibasic dihydrate E00498 6451167 Buffering agent; Complexing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Water E00035 962 Solvent
Certolake sunset yellow E00351 61817 Colorant
Colcothar yellow E00436 518696 Colorant
Sorbitan tristearate E00516 17800859 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 44 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ranitidine 150 mg capsule 150 mg Oral Capsule Oral
Ranitidine 300 mg capsule 300 mg Oral Capsule Oral
Ranitidine 300 mg tablet 300 mg Oral Tablet Oral
Ranitidine 150 mg tablet 150 mg Oral Tablet Oral
Ranitidine 75 mg tablet 75 mg Oral Tablet Oral
Ranitidine Hydrochloride eq 15 mg base/mL syrup eq 15 mg base/mL Syrup Oral
Ranitidine Hydrochloride eq 25 mg base/mL injectable eq 25 mg base/mL Injectable Injection
Ranitidine Hydrochloride eq 150 mg base tablet eq 150 mg base Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Ranitidine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1234).
3 Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000.
4 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5 FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection
6 Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet. 1984 May-Jun;9(3):211-21. doi: 10.2165/00003088-198409030-00003.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
11 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
12 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
13 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
14 Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
15 Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76.
16 Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
17 Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 2002 Nov;54(11):1559-63. doi: 10.1211/002235702117.
18 Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos. 2004 Nov;32(11):1247-53. doi: 10.1124/dmd.104.000026. Epub 2004 Jul 30.
19 Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res. 2002;22(2):29-35.
20 [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
21 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
22 Albert KS, Welch RD, DeSante KA, DiSanto AR "Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture." J Pharm Sci 68 (1979): 586-8. [PMID: 435335]
23 Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
24 Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
25 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
26 Product Information. Tagamet (cimetidine). SmithKline Beecham, Philadelphia, PA.
27 Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
28 Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
29 Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
30 Cerner Multum, Inc. "Australian Product Information.".
31 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 Katende RS, Dimich I "Resistance to nondepolarizing muscle relaxants in a patient treated with ranitidine." Mt Sinai J Med 54 (1987): 330-1. [PMID: 2955219]
34 Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358]
35 Adachi M, Hinatsu Y, et.al "Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers." Eur J Pharm Sci 76 (2015): 225-30. [PMID: 25988287]
36 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
37 Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
38 Knupp CA, Graziano FM, Dixon RM, Barbhaiya RH "Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus." Antimicrob Agents Chemother 36 (1992): 2075-9. [PMID: 1444287]
39 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
40 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
41 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
42 Product Information. Zantac (ranitidine). Glaxo Wellcome, Research Triangle Park, NC.
43 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
44 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
46 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
47 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
48 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
49 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
50 Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 Martin BK "Effect of ranitidine on procainamide disposition." Br J Clin Pharmacol 19 (1985): 858-60. [PMID: 4027133]